OR WAIT null SECS
Neal D. Shore, MD, FACS, discusses the importance of multidisciplinary care for patients with advanced prostate cancer.
At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Neal D. Shore, MD, FACS, regarding the importance of multidisciplinary care for patients with advanced prostate cancer.
Incorporating a multidisciplinary approach for patients with advanced prostate cancer is essential in order to provide patients with further therapeutic benefit and improve quality of life.
When we are taking care of our patients with advanced cancers, and advanced prostate cancer is no exception, fatigue and the spectrum of neurocognitive maladies, as well as cardio-oncologic maladies become that much more important. All across the field of cancer in its totality, [we] are recognizing this. [By] incorporating a multidisciplinary approach, either as the [urologic] oncologist, the medical oncologist, the radiation oncologist, the nuclear medicine radiologist, or the pathologist—whoever is really involved in the care of the patient—appreciating that the spectrum of cardio-oncologic and neuro-oncologic differences in drugs of the same therapeutic class need to be studied [is important]. It may not affect all patients, it may not affect most patients, but there [are] clearly going to be certain patients or a significant population of patients [for whom] the right drug selection and comparable therapeutic mechanism of action classes could really benefit a patient and help their quality of life.